WO2008093677A1 - 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 - Google Patents

血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 Download PDF

Info

Publication number
WO2008093677A1
WO2008093677A1 PCT/JP2008/051312 JP2008051312W WO2008093677A1 WO 2008093677 A1 WO2008093677 A1 WO 2008093677A1 JP 2008051312 W JP2008051312 W JP 2008051312W WO 2008093677 A1 WO2008093677 A1 WO 2008093677A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
derivatives
inhibiting activity
halogeno
hydrogen
Prior art date
Application number
PCT/JP2008/051312
Other languages
English (en)
French (fr)
Inventor
Takahiro Honda
Koushi Fujisawa
Hiroyuki Aono
Masakazu Ban
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Priority to KR1020097015971A priority Critical patent/KR101475540B1/ko
Priority to US12/449,159 priority patent/US8063034B2/en
Priority to CA002676163A priority patent/CA2676163A1/en
Priority to EP08704094A priority patent/EP2128156A4/en
Priority to CNA2008800034142A priority patent/CN101600712A/zh
Publication of WO2008093677A1 publication Critical patent/WO2008093677A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

式（I）で表される化合物又はその塩。式中、環Ａはベンゼン環、チオフェン環又はピリジン環を示し；Ｒａは水素原子、ハロゲン原子、アルキル基又はアルコキシ基を示し；環Ｂはピリジン環、ピリミジン環又はキノリン環を示し；環Ｃはベンゼン環、ピリジン環、キノリン環又はイソキノリン環を示し；ＸとＹは同一又は異なって酸素原子又は硫黄原子を示し（但し、Ｘが硫黄原子かつＹが酸素原子の場合を除く）；Ｒ１は水素原子、ハロゲン原子、アミノ基、シクロアルキルアミノ基、アルキルカルボニルアミノ基、アルキルオキシカルボニルアミノ基、アルキルアミノカルボニル基又は非芳香族複素環基を示し；Ｒ２とＲ２’は同一又は異なって水素原子、ハロゲン原子、アルキル基、ハロゲノアルキル基又はハロゲノアルコキシ基を示す。 　　【化１】
PCT/JP2008/051312 2007-01-29 2008-01-29 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 WO2008093677A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020097015971A KR101475540B1 (ko) 2007-01-29 2008-01-29 혈관 신생 저해 활성을 갖는 신규 옥사디아졸 유도체 및 티아디아졸 유도체
US12/449,159 US8063034B2 (en) 2007-01-29 2008-01-29 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
CA002676163A CA2676163A1 (en) 2007-01-29 2008-01-29 Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
EP08704094A EP2128156A4 (en) 2007-01-29 2008-01-29 NEW OXADIAZOL DERIVATIVES AND THIADIAZONE DERIVATIVES WITH THE NEOVASCULARIZATION HEMMENDER EFFECT
CNA2008800034142A CN101600712A (zh) 2007-01-29 2008-01-29 具有血管新生抑制活性的新型噁二唑衍生物及噻二唑衍生物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-018059 2007-01-29
JP2007018059 2007-01-29
JP2007083153 2007-03-28
JP2007-083153 2007-03-28

Publications (1)

Publication Number Publication Date
WO2008093677A1 true WO2008093677A1 (ja) 2008-08-07

Family

ID=39673984

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/051312 WO2008093677A1 (ja) 2007-01-29 2008-01-29 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
PCT/JP2008/051308 WO2008093674A1 (ja) 2007-01-29 2008-01-29 キナーゼ阻害活性を有する新規チアジアゾール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051308 WO2008093674A1 (ja) 2007-01-29 2008-01-29 キナーゼ阻害活性を有する新規チアジアゾール誘導体

Country Status (7)

Country Link
US (1) US8063034B2 (ja)
EP (1) EP2128156A4 (ja)
JP (2) JP5216341B2 (ja)
KR (1) KR101475540B1 (ja)
CN (2) CN101600712A (ja)
CA (1) CA2676163A1 (ja)
WO (2) WO2008093677A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897774B2 (en) * 2005-03-03 2011-03-01 Santen Pharmaceutical Co., Ltd. Cyclic compound having quinolylalkylthio group
JP2017071634A (ja) * 2010-03-24 2017-04-13 アミテック セラピューティック ソリューションズ，インク． キナーゼ阻害に役立つ複素環式化合物
CN108794460A (zh) * 2018-05-11 2018-11-13 贵州医科大学 一种1,2,4-噁二唑-3,4-二氢喹啉型化合物及其制备方法和用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2012128161A1 (ja) * 2011-03-18 2012-09-27 東洋紡績株式会社 フレキシブルブーツ用ポリエステルブロック共重合体組成物
CN102584639B (zh) * 2011-12-22 2013-09-18 山东京博控股股份有限公司 对三氟甲氧基苯胺基甲酰肼的合成方法
TW201336526A (zh) 2012-01-31 2013-09-16 參天製藥股份有限公司 非水性液體組成物
JP6271422B2 (ja) 2012-06-25 2018-01-31 協和発酵キリン株式会社 ４，６−ヘキサデカジエン−２，４−ジカルボン酸誘導体
CN103288817A (zh) * 2013-07-02 2013-09-11 天津理工大学 一种基于1,3,4-噻二唑和1,3,4-噁二唑的希夫碱衍生物及其制备方法和应用
CN103408540B (zh) * 2013-08-22 2016-05-18 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途及其用途
TW201609145A (zh) 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
EP3504204A4 (en) 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
JPWO2018230713A1 (ja) 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
CN108774215A (zh) * 2018-08-15 2018-11-09 翟学旭 含氮杂环类衍生物及其在视网膜新生血管疾病中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1998035958A1 (en) 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO2000027819A2 (de) 1998-11-10 2000-05-18 Schering Aktiengesellschaft Anthranilsäureamide und deren verwendung als arzneimittel
WO2001055114A1 (en) 2000-01-27 2001-08-02 Novartis Ag 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
WO2004052280A2 (en) 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
JP2005509616A (ja) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
WO2005085201A1 (ja) 2004-02-17 2005-09-15 Santen Pharmaceutical Co., Ltd. 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
WO2006002383A2 (en) 2004-06-23 2006-01-05 Bayer Pharmaceuticals Corporation 2-aminoarylcarboxamides useful as cancer chemotherapeutic agents
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
WO2006093253A1 (ja) 2005-03-03 2006-09-08 Santen Pharmaceutical Co., Ltd. キノリルアルキルチオ基を有する新規環式化合物
WO2006106914A1 (ja) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. ピリミジニルアルキルチオ基を有する新規環式化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04746B1 (et) * 1997-06-24 2006-12-15 Janssen Pharmaceutica N.V. 5-asendatud-1,2,4-tiadiasolüülderivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1998035958A1 (en) 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO2000027819A2 (de) 1998-11-10 2000-05-18 Schering Aktiengesellschaft Anthranilsäureamide und deren verwendung als arzneimittel
WO2001055114A1 (en) 2000-01-27 2001-08-02 Novartis Ag 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
JP2005509616A (ja) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
WO2004052280A2 (en) 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2005085201A1 (ja) 2004-02-17 2005-09-15 Santen Pharmaceutical Co., Ltd. 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
WO2006002383A2 (en) 2004-06-23 2006-01-05 Bayer Pharmaceuticals Corporation 2-aminoarylcarboxamides useful as cancer chemotherapeutic agents
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
WO2006093253A1 (ja) 2005-03-03 2006-09-08 Santen Pharmaceutical Co., Ltd. キノリルアルキルチオ基を有する新規環式化合物
WO2006106914A1 (ja) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. ピリミジニルアルキルチオ基を有する新規環式化合物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Molecular Medicine", vol. 35, 1998, NAKAYAMA SHOTEN, article "Molecular Mechanism of Symptom and Pathology", pages: 73 - 74
"rotein, Nucleic Acid, and Enzyme", vol. 118, 2000, KYORITSU SHUPPAN, article "Forefront Drug Development", pages: 2 - 1187
BIOORG, MED. CHEM. LETT., vol. 16, no. 5, 2006, pages 1440 - 1444
BIOORG, MED. CHEM. LETT., vol. 16, no. 7, 2006, pages 1913 - 1919
KISELYOV A.S. ET AL.: "Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II", BIOORG. MED. CHEM. LETT., vol. 16, no. 5, 2006, pages 1440 - 1444, XP025106372 *
KISELYOV A.S. ET AL.: "Inhibitors of VEGF receptors-1 and -2 based on the 2-(pyridine-4-yl)ethyl)pyridine template", BIOORG. MED. CHEM. LETT., vol. 16, no. 7, 2006, pages 1913 - 1919, XP025106994 *
OUYANG X. ET AL.: "Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines", BIOORG. MED. CHEM. LETT., vol. 16, no. 5, 2006, pages 1191 - 1196, XP025106318 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897774B2 (en) * 2005-03-03 2011-03-01 Santen Pharmaceutical Co., Ltd. Cyclic compound having quinolylalkylthio group
JP2017071634A (ja) * 2010-03-24 2017-04-13 アミテック セラピューティック ソリューションズ，インク． キナーゼ阻害に役立つ複素環式化合物
US10214513B2 (en) 2010-03-24 2019-02-26 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
CN108794460A (zh) * 2018-05-11 2018-11-13 贵州医科大学 一种1,2,4-噁二唑-3,4-二氢喹啉型化合物及其制备方法和用途
CN108794460B (zh) * 2018-05-11 2021-05-28 贵州医科大学 一种1,2,4-噁二唑-3,4-二氢喹啉型化合物及其制备方法和用途

Also Published As

Publication number Publication date
US8063034B2 (en) 2011-11-22
EP2128156A4 (en) 2011-05-18
JP2008266294A (ja) 2008-11-06
US20100016354A1 (en) 2010-01-21
CA2676163A1 (en) 2008-08-07
EP2128156A1 (en) 2009-12-02
CN103224493A (zh) 2013-07-31
JP5216341B2 (ja) 2013-06-19
JP2008266295A (ja) 2008-11-06
WO2008093674A1 (ja) 2008-08-07
KR20090104087A (ko) 2009-10-05
KR101475540B1 (ko) 2014-12-22
CN101600712A (zh) 2009-12-09

Similar Documents

Publication Publication Date Title
WO2008093677A1 (ja) 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
WO2005095395A3 (en) Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
MX2007000035A (es) Inhibidores de cetp.
WO2005095409A3 (en) Tetrahydroquinoline derivatives and a process for preparing the same
MX2011007455A (es) Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1).
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
MY152972A (en) Azabicyclo compound and salt thereof
TW200800947A (en) Trisubstituted amine compound
WO2009016841A1 (ja) オキソピラジン誘導体及び除草剤
WO2007081570A3 (en) Cholesteryl ester transfer protein inhibitors
JO3114B1 (ar) مركبات بيريدازينون
EP2845587A3 (en) Melanin production inhibitor
WO2006071471A3 (en) 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
WO2009057784A1 (ja) 複素環化合物
WO2009069736A1 (ja) 含窒素化合物
WO2008111604A1 (ja) 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬
WO2008078725A1 (ja) チアゼピン誘導体
EP1642880A4 (en) PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2008111239A1 (ja) 帯電防止剤およびその用途
WO2008140066A3 (en) Pyridone derivatives as p38a mapk inhibitors
WO2008105058A1 (ja) スルホンアミド化合物
TW200609218A (en) Bicyclic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880003414.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704094

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2676163

Country of ref document: CA

Ref document number: 2008704094

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449159

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020097015971

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP